61 results about "Diabetic rat" patented technology

The invention provides an exosome, a mesenchymal stem cell and application of the exosome and the mesenchymal stem cell in treatment of type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The exosome secreted by the umbilical cord mesenchymal stem cells of the composite pretreatment group is used for treating the type 2 diabetes mellitus, and the obvious advantages are shown. Compared with a model control group, the exosome has the advantages that the glucose tolerance of diabetic rats treated by the exosome is obviously improved, the blood glucose value is reduced by about 47.5% within 120 minutes, the area under a blood glucose curve (AUC) is reduced by about 50.5%, the serum insulin is increased by about 147.7%, insulin secretion is effectively promoted, the glycosylated hemoglobin level is obviously reduced, and the long-term blood glucose control effect is good. By integrating various indexes, the exosome obtained by the composite pretreatment scheme provided by the invention has a remarkable effect of improving the illness state of rats with type 2 diabetes mellitus, provides a new effective strategy for treatment of type 2 diabetes mellitus, and shows a good application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of a Pucurbita pepo polypeptide Nacrein-LP20 in preparation of a medicine for promoting wound healing and a preparation method of the Pucurbita pepo polypeptide Nacrein-LP20. The amino acid sequence of the Hepu pearl polypeptide Nacrein-LP20 is as shown in SEQ ID NO: 1 (Sequence Identity Number 1). According to the present invention, the Pucurbita pepo active polypeptide Nacrein-LP20 has characteristics of strong DPPH free radical and hydroxyl free radical removing ability and excellent antioxidant activity, can significantly promote HaCaT cell proliferation in the high glucose environment, and can promote migration and repair of HaCaT cells in the high glucose environment; the traditional Chinese medicine composition has a remarkable healing promoting effect on full-cortical resection wound surfaces of normal rats and diabetic rats.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention discloses a hydrogel microneedle patch and a preparation method and application thereof.The hydrogel microneedle patch is characterized in that a gel main body is obtained by mixing PEG600 and PEG1000 according to the mass ratio of 3: 4, erythromycin, vaccarin and 7-demethylated corticin are loaded, a temperature response type gel microneedle is prepared, DG is in a solid needle shape at the room temperature, and the temperature response type gel microneedle patch is a hydrogel microneedle patch. Under the action of external force, the medicine can penetrate through a biological membrane secreted by bacteria and then is quickly melted into liquid by virtue of body temperature, and loaded medicine is released; in the invention, the wound healing is promoted through the synergistic effect between the hydrogel and the medicine. The hydrogel microneedle patch prepared by the invention can remarkably promote rapid healing of a staphylococcus aureus infected wound surface and can remarkably promote rapid healing of a back wound surface of a diabetic rat.

The invention relates to a pH-responsive copper hydrogen phosphate-loaded hydrogel with multiple enzyme-like activities and a preparation method and application thereof. The material mainly shows catalase-like activity in a neutral microenvironment, and can remove H2O2 and relieve oxidative stress; in a weakly acidic microenvironment, the compound mainly shows peroxidase-like activity and catalyzes H2O2 to generate. OH bacteria with higher toxicity; meanwhile, the inherent osteogenesis promoting performance of copper synergistically enhances bone regeneration, the biocompatibility, the oxidation resistance, the osteogenesis promoting capacity under the oxidative stress condition and the antibacterial efficiency under the weak acid condition of the SA / CuHP hydrogel are evaluated through in-vitro experiments, and a type II diabetes rat periodontitis model is established; the in-vivo antibacterial and osteogenesis promoting effects and the biological safety performance of the compound are verified, and a new strategy is provided for treatment of periodontitis with diabetes mellitus.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention discloses a blood-glucose-reducing traditional Chinese medicine composition for inhibiting metabolic inflammation and a preparation method of the blood-glucose-reducing traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-40 parts of herba eupatorii, 5-7 parts of rhizoma coptidis, 10-20 parts of ginseng, 10-20 parts of poria cocos, 10-20 parts of roasted rhizoma atractylodis macrocephalae, 5-7 parts of honey-fried licorice root, 10-20 parts of agastache rugosus, 8-10 parts of radix aucklandiae, 12-22 parts of radix puerariae, 8-10 parts of stiff silkworm, 10-20 parts of ramulus euonymi, 10-20 parts of ramulus mori and 2-5 parts of cortex cinnamomi. The traditional Chinese medicine composition disclosed by the invention can be used for inhibiting the proinflammatory factor IL-6 level (Plt; 0.05), increasing the level of anti-inflammatory factor IL-22 (Plt; in small intestine tissues of rats with type 2 diabetes, the traditional Chinese medicine composition disclosed by the invention can be used for relieving inflammation infiltration; immunohistochemical detection results show that the traditional Chinese medicine composition can improve the expression level of AHR and IL-22 in small intestine tissues, provides a scientific basis for inhibiting metabolic inflammation by using a detoxification and turbidity dissolving method so as to improve insulin resistance and treat type 2 diabetes, and also provides a new treatment idea and drug selection.

A compound represented by formula (I) and a preparation method thereof, and a pharmaceutically acceptable salt thereof, a metabolic precursor thereof, a metabolite thereof, an isomer thereof or a prodrug thereof; experiments show that the indole alkaloid not only promotes axon growth of peripheral sensory neurons, improves the nerve conduction velocity and anesthesia symptom of diabetic rats, but also promotes healing of foot ulcer wounds of diabetic rats, thus having good therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet; they als show that the indole alkaloid also obviously reduces a degree of pulmonary fibrosis induced by bleomycin in mice, and plays a role in protecting lung tissues.

The invention relates to the technical field of medical biological materials, in particular to hydrogel capable of self-adaptively releasing exosomes and a preparation method and application thereof.The hydrogel comprises a precursor, a buffer solution and the exosomes, the precursor is dissolved in the buffer solution to form a matrix of a three-dimensional network structure, and the exosomes are loaded in the three-dimensional network structure of the matrix; the precursor comprises HA-ADH and OHA-TK-CP, and the mass ratio of the HA-ADH to the OHA-TK-CP is (1: 5)-(1: 1); in-vivo and in-vitro research results show that the hydrogel has excellent self-repairing capability, remarkable antibacterial activity, efficient exosome release and effective ROS (reactive oxygen species) reduction capability, the wound healing of MRSA-infected diabetic rats is accelerated by the synergistic anti-inflammatory effect and tissue regeneration promotion effect of the hydrogel, and scars are relatively small after the wound healing; the preparation method is simple to operate, mild in reaction condition and beneficial to large-scale production.

The invention provides a pegylation modification method of erythropoietin. According to the invention, EPO is modified by adopting different modified PEGs, so that the EPO molecule with prolonged plasma half-life period is obtained, and the problems of short retention time and low activity of the EPO molecule in plasma are solved. According to the invention, the prepared mPEG-SPA-EPO is further subjected to purification and identification. The composition is further prepared by adopting the prepared modified EPO, and the application of the composition is identified. The EPO modified by PEG is prepared into the composition to be applied to diabetic rats, compared with recombinant EPO, the composition has better effects of reducing blood sugar and body weight, and mesenchymal stem cells are added into the composition, so that the blood sugar reducing effect of the rats is further enhanced. The composition prepared by the invention can be applied to preparation of medicines for reducing blood sugar and treating diabetes, has a relatively long half-life period in vivo, and has a relatively good application prospect.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

The present application belongs to the field of biological medicine, and relates to an in-situ spraying particle-gel composite as well as a preparation method and application thereof. The present application prepares a drug-loaded particle-gel composite material, which can be rapidly gelled in-situ in the form of spraying. In a wound infection model of diabetic rats, the composite material exhibits good photothermal activation TRPV1 channel-mediated local analgesia, as well as anti-inflammatory, antibacterial, antioxidant, hemostatic and wound healing-promoting multifunctional therapeutic effects. Through in-vitro and in-vivo material characterization, as well as histopathological examination of animal experiments, it is confirmed that the composite gel material has good biological safety and degradability, and is a local anesthetic biomaterial preparation which is expected to be clinically transformed for chronic wound analgesia and healing-promoting therapeutic effects.

The invention belongs to the technical field of construction of experimental animal models, and particularly relates to a construction method and application of a recombinant inbred line type 2 diabetes mellitus rat model, in parent rats, female rats are SD (fa + / +) or Wistart (fa + / +), male rats are Zucker (fa + / -), heterozygote (fa + / -) female rats in filial generations obtained through hybridization are backcrossed with male parents until an F6 generation, and the female rats and the male rats are subjected to cross breeding to obtain the recombinant inbred line type 2 diabetes mellitus rat model. And hybridizing the F6 generation heterozygote (fa < + / ->) female rat with the F6 generation heterozygote (fa < + / ->) male rat to obtain a homozygote (fa <- / ->) SD / Zucker or Wistart / Zucker rat which is the recombinant inbred line type 2 diabetes mellitus rat. The obtained rats cannot express functional leptin receptors, have hyperappetite and autonomous polydipsia and polyphagia, and are very in line with real occurrence scenes of type 2 diabetes mellitus caused by overnutrition of diet under normal diet conditions of human beings.

The present invention provides a method for constructing a rat model simulating the clinical characteristics of peripheral arterial disease, comprising the following steps: Step 1: A unilateral femoral artery of a diabetic rat is ligated with an Ameroid constrictor ring, and the rat is raised for a period of time; Step 2: The femoral artery of the rat surviving after being raised in Step 1 is ligated. In Step 1 and Step 2, the ligation of the Ameroid constrictor ring and the femoral artery ligation are both located on the same side femoral artery of the rat. The present invention establishes a chronic limb ischemia animal model conforming to the clinical characteristics of peripheral arterial disease. The present invention intends to induce type 2 diabetes in rats by feeding them with a high-fat and high-sugar diet, use an Ameroid constrictor ring on the femoral artery to cause progressive limb ischemia, and then ligate the femoral artery to cause vascular occlusion to simulate critical limb ischemia. The "staged" chronic limb ischemia in diabetic rats provides a suitable animal model for the basic research of peripheral arterial disease.

The present application relates to a kind of porous scaffold for repairing bone defect loaded with black phosphorus active oxygen elimination and slow-release drug and its preparation method;The scaffold includes the amino cation polymer grafted with the phenylboronic acid (PBA) and cyclodextrin (CD) that can eliminate active oxygen, black phosphorus nanosheet (BP) and scaffold material poly (lactic acid-glycolic acid) (PLGA).The porous scaffold loads a large number of black phosphorus nanosheet that can be hydrolyzed into bone repair nutrients, and the porous structure provides sufficient space for cell migration and growth, realizes the good repair of bone.Active oxygen elimination ability, can eliminate active oxygen in diabetic microenvironment.In addition, cyclodextrin can load a variety of drugs, such as osteogenic differentiation induction drug, and realize the slow release of drug.The porous scaffold has good biocompatibility, and the degradation product is harmless to human body, can be used for the tissue repair of bone defect, can be widely applied in the field of biological medicine and tissue engineering, and has been proved to have good repair ability in the diabetic rat skull defect model.

The invention belongs to the technical field of fermentation, and particularly relates to medicinal and edible fermentation liquor with a blood sugar reducing effect as well as a preparation method and application of the medicinal and edible fermentation liquor. The fermentation liquor is prepared from the following components in parts by weight: 50 to 75 parts of fructus corni, 45 to 65 parts of stigma croci, 40 to 60 parts of fructus physalis pubescentis, 35 to 50 parts of rumex hanus, 13 to 20 parts of an enzyme preparation and 0.17 to 0.25 part of a leavening agent. The obtained fermentation liquor has the effect of inhibiting alpha-glucosidase through in-vitro verification, the fasting blood glucose level of rats with type 2 diabetes mellitus can be reduced through rat experiment verification, and the effect of reducing blood glucose can be achieved through a PI3K / Akt channel.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

The invention discloses a targeting stem cell exosome composition and application thereof in treating diabetic foot ulcer. According to the composition, a mesenchymal stem cell exosome is modified through genetic engineering, specific targeting fusion polypeptide is expressed on the surface of the mesenchymal stem cell exosome, anti-inflammatory miR-146a and a pro-angiogenic factor VEGF are loaded, and then the mesenchymal stem cell exosome is compounded with temperature-sensitive hyaluronic acid hydrogel to form a sustained release system. The sequence of the fusion polypeptide is as shown in SEQ ID NO: 1, and the targeting of exosomes to diabetic inflammation parts is remarkably improved; the stability of miR-146a is enhanced through chemical modification, and the miR-146a cooperates with VEGF to inhibit inflammation and promote revascularization. In-vitro experiments show that the composition reduces the levels of TNF-alpha and IL-6 by 85% and 88% respectively, and the cell migration rate reaches 99.3%; in-vivo experiments show that the wound healing rate of diabetic rats reaches 99.6% on the 14th day, and the collagen deposition area proportion is increased to 77.5%. The invention has targeting property, function synergy and slow release performance, and provides an efficient treatment strategy for diabetic foot ulcer.

The application belongs to the field of biomedical materials, and discloses a multifunctional hydrogel suitable for diabetic wound healing. The hydrogel is compounded by HA-Tris, EPL-Cpb and MXene / Mn composite nanoparticles in a mass ratio of 2:1:(0-0.2), and is rapidly crosslinked in 1 min through a triple mechanism, with a crosslinking efficiency increased by more than 80% compared with traditional methods and a yield of more than 99.5%. The application realizes chemical-photothermal dual-mode antibiosis through precise optimization of the ratio and reaction conditions and the function synergy of the components, with an inhibition rate of 96.86% and 97.23% for Escherichia coli and Staphylococcus aureus, which is increased by more than 62% compared with traditional silver-containing dressings; the hydrogel has a ROS clearance rate of 92.5% and an in-situ oxygen production rate increased by 58% compared with traditional methods, and can efficiently stop bleeding within 30 s, with a blood loss reduced by 90.3% compared with the blank group. The hydrogel has excellent biocompatibility and can comprehensively improve the pathological microenvironment of diabetic wounds, shortening the healing period of full-thickness skin wounds of diabetic rats from 21 days to 10 days, and providing a new and efficient biomedical material for the treatment of diabetic wounds.

The invention relates to application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes, and belongs to the technical field of photomedicine. The invention provides application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes. According to the invention, a diabetic rat model is established, near-infrared light and blue light are adopted to carry out phototherapy on diabetic rats, and blood sugar and blood fat related indexes of the diabetic rats and changes of different tissue forms and behaviors of the rats are measured; results show that the near-infrared light and the blue light can effectively improve blood sugar and blood fat related indexes of the rats after phototherapy of the rats, and can also improve tissue morphology and cognitive behaviors of the diabetic rats, which indicates that the phototherapy of the near-infrared light or the blue light has the effects of treating diabetic blood sugar and cognition, can reduce dependence of patients on medicines, and can improve the curative effect of the patients on diabetes mellitus. And new experimental basis and theoretical support are provided for clinical non-drug intervention of diabetes.

The invention provides a multifunctional polyrotaxane hydrogel FDS. NO loaded on the FDS hydrogel has the capability of promoting cell migration, proliferation and angiogenesis at the same time. The FDS hydrogel can inhibit the activation of a downstream pathway by adsorbing extracellular DNA (cfDNA), thereby reducing the release of inflammatory factors. Animal experiments further prove that the FDS hydrogel not only can sterilize and promote cell proliferation and reconstruction of a diabetic wound area, but also can promote angiogenesis of a diabetic rat wound. Therefore, the FDS hydrogel has remarkable advantages in diabetes wound management.

The application discloses a novel brown algae polysaccharide SARP for promoting healing of diabetic ulcers and a preparation and application thereof. A novel SARP is obtained through Sephacryl S-300 / HR gel column separation and purification, and the molecular weight of the SARP is about 45.4 kDa, which is composed of mannuronic acid (76.56%), guluronic acid (18.89%) and a small amount of glucuronic acid (4.55%). Compared with alginate separated from other brown algae, the SARP has a higher content of mannuronic acid. The SARP shows a better in-vitro antioxidant capacity, and can obviously reverse the cell damage of HUVECs caused by H2O2 and high sugar in the HUVECs. In addition, the SARP can promote the migration and tubular formation of the HUVECs. In-vivo experiments further show that the SARP can promote the healing of diabetic ulcer in rats, and can reduce the oxidative stress, inflammation level and lipid disorder in the rats. The SARP has a simple purification route, can be prepared in a large amount, and is a very promising novel drug for treating diabetic foot ulcers.

The invention provides application of asiatic toddalia root lactone in preparation of a medicine for promoting angiogenesis, relates to the technical field of biomedicine, and finds that the asiatic toddalia root lactone can promote angiogenesis of zebra fish after ischemia for the first time and is expected to provide a new theoretical basis and a potential intervention target for treatment of angiogenesis after ischemia. Experiments prove that after the Asiatic toddalia root lactone intervenes in the zebrafish of the microvascular deletion model, the Asiatic toddalia root lactone has the effect of promoting the Meanwhile, research on endothelial cells finds that after the asiatic toddalia root lactone intervenes an endothelial cell glucose-deficiency and hypoxia model, the activity of the asiatic toddalia root lactone is obviously improved; scratch experiments show that the asiatic toddalia root lactone can obviously promote cell migration. In MCAO model rats, the asiatic toddalia root lactone can increase the local cerebral blood flow perfusion amount of the rats and reduce the TTC staining infarction rate, which indicates that the asiatic toddalia root lactone resists cerebral ischemia by promoting the revascularization; in diabetic wounded rats, the asiatic toddalia root lactone can promote wound healing of the diabetic rats.

The invention discloses a method for establishing a type II diabetes mellitus rat model in the technical field of biology, which comprises the following steps of: regulating and controlling dynamic pathology evolution, reproducing the natural disease course of type II diabetes mellitus in stages from insulin resistance-beta cell injury-multi-organ complications-flora intervention and nerve regulation, and establishing a type II diabetes mellitus rat model. The animal model is used for overcoming the defects of a traditional model in the aspect of simulating complex pathological characteristics, the animal model capable of more comprehensively reproducing the multi-dimensional pathological characteristics of the human type II diabetes mellitus is constructed by optimizing an induction strategy and integrating multi-factor intervention, and a more reliable tool is provided for diabetes mellitus mechanism research and drug development.

The invention belongs to the field of experimental animal models, and particularly relates to a feed for inducing type II diabetes mellitus and application thereof, the feed comprises the following components by weight: 450-550 parts of conventional components, 10-150 parts of rapeseed oil with trans fatty acid content of 63-67 g / L, 30-170 parts of lard, and 170-180 parts of sucrose; the conventional components consist of the following components in parts by weight: 200 parts of casein, 3 parts of L-cystine, 72.8 parts of corn starch, 100 parts of maltodextrin, 50 parts of cellulose, 25 parts of soybean oil, 10 parts of trace elements, 10 parts of vitamins, 2 parts of choline bitartrate, 0.05 part of a coloring agent, 13 parts of calcium hydrophosphate, 5.5 parts of calcium carbonate and 16.5 parts of potassium citrate. Compared with a commercially available feed D12451, the feed provided by the invention can efficiently induce a stable and typical type II diabetes rat model.

The invention discloses an application of an arctigenin derivative or a pharmaceutically acceptable salt thereof in preparation of drugs for treating diabetic peripheral neuropathy. A large number of experimental screening results show that the arctigenin derivative and the pharmaceutically acceptable salt thereof can significantly improve the nerve conduction velocity and sensory deficiency symptoms of diabetic rats, thereby achieving the effect of treating peripheral neuropathy.

The application belongs to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine composition, a preparation method and application thereof. One of the traditional Chinese medicine compositions comprises the following raw materials in parts by weight: Cyclobalanopsis glauca 50-80 parts, tartary buckwheat 30-50 parts, polygonatum 30-50 parts, honeysuckle 30-50 parts, Poria cocos 10-20 parts, gordon euryale seed 10-20 parts, lotus seed 10-20 parts, medlar 10-20 parts, angelica 10-20 parts, yam 5-15 parts, hawthorn 5-15 parts, and sour jujube seed 5-15 parts. The compound preparation has a good blood glucose-lowering effect, can correct the lipid metabolism disorder of diabetic rats, and reduce liver function damage, has a certain protective effect on the liver, and can be applied to the preparation of a medicine for treating non-alcoholic fatty liver. On this basis, in addition to adding part of the medicinal materials, the traditional Chinese medicine composition can also be applied to the preparation of a medicine for treating chronic obstructive pulmonary disease and a medicine for treating bacterial pneumonia.

The invention belongs to the field of development and utilization of beautiful millettia roots, and particularly relates to a beautiful millettia root flower extract and a preparation method and application thereof. Fresh flower buds in the initial flowering period of beautiful millettia roots are adopted as raw materials, fermentation liquor is prepared through fermentation of lactobacillus, lactobacillus casei and lactobacillus acidophilus, after sterilization, cellulase, pectin lyase and cellobiohydrolase are added for enzymolysis, enzymatic hydrolysate is obtained, after enzyme deactivation of the enzymatic hydrolysate, alcohol precipitation is conducted to remove precipitates, and the finished product is obtained. The prepared millettia specisoa flower extract can reduce blood sugar of rats with type 2 diabetes mellitus and regulate intestinal flora of the rats, and a new candidate medicine is provided for treatment of diabetes mellitus.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation method and application of a periplaneta americana extract. The periplaneta americana extract prepared by the method disclosed by the invention contains relatively high bioactive substances; the invention also provides application of the extract in preparation of drugs for treating diabetic peripheral neuropathy, pharmacological experiments prove that the periplaneta americana extract has a certain improvement effect on MNCV decrease of diabetic rats, shows a certain shortening effect on action potential refractory period, can prolong the first licking time of mice, and has a good treatment effect on diabetic peripheral neuropathy. The periplaneta americana extract can improve the pain threshold value of mice, and has an obvious analgesic effect and an effect of treating diabetic peripheral neuropathy.

The invention provides a magnesium oxide-loaded asymmetric short fiber aerogel scaffold as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering materials. The preparation method comprises the following steps: adding MgO nanoparticles into a PLLA / Gelatin solution, and carrying out electrostatic spinning, crushing, freeze drying and crosslinking to obtain the porous short fiber aerogel scaffold (GP-coated MgO). The GP-coated MgO aerogel stent has a three-dimensional short fiber structure, and can release loaded MgO nanoparticles in a progressive and continuous manner while wound exudate is slowly absorbed. In-vivo and in-vitro experiments prove that the GP-coated MgO aerogel scaffold has biocompatibility and is very effective in the aspects of inhibiting inflammatory response and slowing down cell senescence. In addition, the GP-coated MgO significantly accelerates vascular reconstruction and epithelization, and promotes wound repair at the skin defect position of a diabetic rat.